# OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

> **NCT03487666** · PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 45 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03487666
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2021-11-03
- **Final completion:** 2024-05-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487666, "OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03487666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*